Iran (Islamic Republic of)Tuberculosis profile
Population  2014 78 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.7 (1.9–3.7) 3.5 (2.4–4.7)
Mortality (HIV+TB only) 0.11 (0.07–0.15) 0.14 (0.09–0.19)
Prevalence  (includes HIV+TB) 26 (13–43) 33 (17–55)
Incidence  (includes HIV+TB) 17 (14–20) 22 (18–26)
Incidence (HIV+TB only) 0.4 (0.3–0.52) 0.51 (0.38–0.66)
         
Case detection, all forms (%) 60 (50–74)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 0.8 (0.3–1.4) 12 (6.2–19)
MDR-TB cases among notified pulmonary
TB cases
55 (21–96) 76 (38–110)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 5 601   339
Pulmonary, clinically diagnosed 1 251   69
Extrapulmonary 2 869   62
       
Total new and relapse 10 191    
Previously treated, excluding relapses 204    
Total cases notified 10 395    
Among 10 191 new and relapse cases:
350 (3%) cases aged under 15 years; male:female ratio: 1.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 135 (20%) 237 (35%) 1 535
Laboratory-confirmed RR-/MDR-TB cases     48
Patients started on MDR-TB treatment ***     53
TB/HIV 2014 Number (%)
TB patients with known HIV status 3 009 (29)
HIV-positive TB patients 272 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 55 (20)
HIV-positive TB patients on antiretroviral therapy (ART) 100 (37)
HIV-positive people screened for TB 8 233  
HIV-positive people provided with IPT 181  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (87) 10 884
Previously treated cases, excluding relapse, registered in 2013 (82) 305
HIV-positive TB cases, all types, registered in 2013 (66) 284
RR-/MDR-TB cases started on second-line treatment in 2012 (48) 62
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.5
Culture (per 5 million population) 3.5
Drug susceptibility testing (per 5 million population) 0.8
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-02-10 Data: www.who.int/tb/data